NEO Estados financieros: Análisis de Neogenomics Inc AI

Inicio

Acciones

NEO

NEO Financiero

Neogenomics Inc

$11.38

1.88%

$0.21

Al cierre: Feb 13, 16:00:00 GMT-5

$11.38

Mercado Posterior: Feb 13, 20:00:00 GMT-5

Visión general Pronóstico Ganando Dividendos Finanzas

Ingreso

Balance general

Flujo de efectivo

Anual

Trimestral

NEO Ingreso

Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Ingresos	709	660	591	509	484	444
Crecimiento de los Ingresos (YoY)	10%	12%	16%	5%	9%	9%
Costo de los ingresos	400	370	347	321	297	258
Utilidad bruta	308	290	244	187	187	185
Venta, General y Administración	351	310	279	277	229	169
Investigación y Desarrollo	35	29	25	28	21	8
Gastos de Operación	400	375	341	341	290	197
Otras Ingresos (Gastos) No Operativos	0	0	0	0	0	11
Ingreso antes de impuestos	-113	-80	-97	-159	-15	-14
Gasto por Impuesto a la Renta	0	-1	-9	-15	-6	-18
Ingreso Neto	-113	-78	-87	-144	-8	4
Crecimiento de la Utilidad Neta	47%	-10%	-40%	1,700%	-300%	-50%
Acciones en Circulación (Diluidas)	128.41	126.65	125.5	124.2	120	111.8
Cambio de Acciones (YoY)	1%	1%	1%	4%	7%	8%
EPS (Diluido)	-0.88	-0.62	-0.7	-1.16	-0.07	0.04
Crecimiento de EPS	44%	-11%	-40%	1,557%	-275%	-50%
Flujo de efectivo libre	-17	-34	-30	-96	-90	-27
Flujo de efectivo libre por acción	--	--	--	--	--	--
Margen bruto	43.44%	43.93%	41.28%	36.73%	38.63%	41.66%
Margen de operación	-12.97%	-12.87%	-16.24%	-30.05%	-21.28%	-2.47%
Margen de beneficio	-15.93%	-11.81%	-14.72%	-28.29%	-1.65%	0.9%
Margen de flujo de caja libre	-2.39%	-5.15%	-5.07%	-18.86%	-18.59%	-6.08%
EBITDA	-79	-50	-60	-119	-64	9
Margen de EBITDA	-11.14%	-7.57%	-10.15%	-23.37%	-13.22%	2.02%
D&A para EBITDA	13	35	36	34	39	20
EBIT	-92	-85	-96	-153	-103	-11
Margen de EBIT	-12.97%	-12.87%	-16.24%	-30.05%	-21.28%	-2.47%
Tasa de Impuesto Efectiva	0%	1.25%	9.27%	9.43%	40%	128.57%

Estadísticas clave

Cierre Anterior

$11.17

Precio de apertura

$11.32

Rango del día

$11.16 - $11.61

Rango de 52 semanas

$4.72 - $14.73

Volumen

2.5M

Volumen promedio

1.8M

EPS (TTM)

-0.89

Rendimiento de dividendos

Cap. de mercado

$1.4B

¿Qué es NEO?

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.



Características

Copiloto de IA para Acciones y Criptomonedas

Predicción de precios

Seguimiento de Recaudación de Fondos

Temas

Comparación de Criptomonedas

Recursos